Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Modern Pathology

Volumn 27, Issue 7, 2014, Pages 958-971

  Tzankov, Alexandar ^a,b   Xu Monette, Zijun Y ^a   Gerhard, Marc ^b   Visco, Carlo ^c   Dirnhofer, Stephan ^b   Gisin, Nora ^b   Dybkaer, Karen ^d   Orazi, Attilio ^e   Bhagat, Govind ^f   Richards, Kristy L ^g   Hsi, Eric D ^h   Choi, William W L ⁱ   Van Krieken, J Han ^j   Ponzoni, Maurilio ^k   Ferreri, Andrés J M ^k   Ye, Qing ^l   Winter, Jane N ^m   Farnen, John P ⁿ   Piris, Miguel A ^o   Møller, Michael B ^p   You, M James ^a   Mcdonnell, Timothy ^a   Medeiros, L Jeffrey ^a   Young, Ken H ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c SAN BORTOLO HOSPITAL   (Italy)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF HONG KONG   (Hong Kong)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^o HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^p ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

diffuse large B cell lymphoma; FISH; germinal center B cell; MYC; prognosis; rearrangement; translocation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MYC PROTEIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; BCL2 GENE; BCL6 GENE; BREAK APART PROBE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SPECIFIC SURVIVAL; DUAL FUSION PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE REARRANGEMENT; GERMINAL CENTER; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PROBE; MULTIPLE CYCLE TREATMENT; ONCOGENE MYC; OVERALL SURVIVAL; PATHOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR VOLUME; AGED; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE REARRANGEMENT; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RISK ASSESSMENT; TREATMENT OUTCOME; VINCRISTINE;

EID: 84903789487     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.214     Document Type: Article

References (50)

1. Stein H, Warnke RA, ChanWC, et al. Diffuse large B-cell lymphoma, not otherwise specified, In: Swerdlow SC, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France; 2008, pp 233-237
2. Chan WJ. Pathogenesis of diffuse large B cell lymphoma. Int J Hematol 2010;92: 219-230
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403: 503-511
4. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 1937-1947
5. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100: 9991-9996
6. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26: 4587-4594
7. Boerma EG, Siebert R, Kluin PM, et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: A historical review of cytogenetics in the light of todays knowledge. Leukemia 2009;23: 225-234
8. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92: 3152-3162
9. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114: 3533-3537
10. Klapper W, Stoecklein H, Zeynalova S, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within rando-mized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008; 22: 2226-2229
11. Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009;23: 777-783
12. Obermann EC, Csato M, Dirnhofer S, et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol 2009;62: 754-756
13. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology 2008;53: 205-217
14. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood 2009;114: 2273-2279
15. Ueda C, Nishikori M, Kitawaki T, et al. Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma. Int J Hematol 2004; 79: 52-54
16. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117: 2319-2331
17. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol 2011;18: 219-228
18. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30: 3460-3467
19. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein co-expression associated with high-risk gene signatures contributes to the inferior prognosis of activated B-cell subtype of DLBCL. Blood 2013;121: 4021-4031
20. Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2 and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012;118: 4173-4183
21. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30: 3452-3459
22. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25: 579-586
23. Obermann EC, Csato M, Dirnhofer S, et al. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. J Clin Pathol 2009;62: 903-907
24. Tzankov A, Schneider A, Hoeller S, et al. Prognostic importance of BCL6 rearrangements in diffuse large B-cell lymphoma with respect to Bcl6 protein levels and primary lymphoma site. Hum Pathol 2009;40: 1055-1056
25. Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010; 51: 199-212
26. Visco C, Tzankov A, Xu-Monette ZY, et al. BCL2 rearrangement characterizes a subset of patients with diffuse large B cell lymphoma of germinal center origin with poor outcome: A report from an international DLBCL rituximab-CHOP consortium program study. Haematologica 2013;98: 255-263
27. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012;26: 2103-2113
28. McShane LM, Altman DG, Sauerbrei W, et al. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005;41: 1690-1696
29. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. MabThera International Trial (MInT) Group. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-Bcell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9: 435-444
30. Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia 2007;21: 515-523
31. Bertrand P, Maingonnat C, Picquenot JM, et al. Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas. Leukemia 2008;22: 1064-1067
32. Wang HY, Bossler AD, Schaffer A, et al. A novel t(3;8) (q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2007;172: 45-53
33. Shiramizu B, Barriga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: Relevance to geography and Epstein-Barr virus association. Blood 1991;77: 1516-1526
34. Pelicci PG, Knowles DM 2nd, Magrath I, et al. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci USA 1986;83: 2984-2988
35. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003;17: 1115-1129
36. Kainz B, Shehata M, Bilban M, et al. Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer 2007;121: 1984-1993
37. Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012;118: 4173-4183
38. Copie-Bergman C, Gaulard P, Leroy K, et al. Immunofluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. J Clin Oncol 2009;27: 5573-5579
39. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28: 3360-3365
40. Cuccuini W, Briere J, Mounier N, et al. MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012;119: 4619-4624
41. Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: A multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol 2009;40: 645-652
42. Haralambieva E, Kleiverda K, Mason DY, et al. Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol 2002;198: 163-170
43. Tapia G, Lopez R, Munöz-Mármol AM, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology 2011;59: 672-678
44. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012;7: 1-9
45. Leucci E, Cocco M, Onnis A, et al. MYC translocationnegative classical Burkitt lymphoma cases: An alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 2008;216: 440-450
46. Craig VJ, Cogliatti SB, Imig J, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011;117: 6227-6236
47. Bonnet M, Loosveld M, Montpellier B, et al. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood 2011; 117: 6650-6659
48. Dunleavy K, Pittaluga S, Wayne S, et al. Myc agressive B-cell lymphomas: Novel therapy of untreated Burkitt lymphoma (BL) and Myc diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol 2011;22(Suppl 4): 071
49. D'Amico M, Gasparoli L, Arcangeli A. Potassium channels: Novel emerging biomarkers and targets for therapy in cancer. Recent Pat Anticancer Drug Discov 2013;8: 53-65
50. Gutman GA, Chandy KG, Grissmer S, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57: 473-508